Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | President | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 842,307 |
Reported balance
After 2026-07-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-09 · Sale · Disposed 48,502 · Balance 842,307 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 822,508 |
Reported balance
After 2026-07-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-10 · Sale · Disposed 19,799 · Balance 822,508 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 822,240 |
Reported balance
After 2026-07-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-10 · Sale · Disposed 268 · Balance 822,240 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 378,291 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 378,291 F5: Includes the unvested portion of the Reporting Person's RSU grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Includes the unvested portion of the Reporting Person's RSU grants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 233 | $40.46 | $9,426.36 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,265 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:19 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 632 | $39.59 | $25,021.89 |
DisclosureSEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,498 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:50 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,675 | $23.68 | $63,344.00 |
DisclosureSEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,286 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:50 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 87 | $24.77 | $2,154.99 |
DisclosureSEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,961 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:50 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,095 | $24.13 | $50,552.35 |
DisclosureSEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,048 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:12 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 116,250 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004270 · doc4.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,250 Underlying: Common Stock · 116,250 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:12 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004270 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,768 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:46 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GiftCommon Stock | 1,207,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054918 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,572,240 F1 · price: Gift to various family trusts over which the reporting person has neither voting nor investment control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034981 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 15:49 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001209191-20-004401 · doc4.xml · derivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 28, 2019 Filed Jun 28, 2019 23:07 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,894 | $7.89 | $38,636.66 |
DisclosureSEC source: 0001209191-19-039547 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,779,240 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $8.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 23:07 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 10,106 | $7.44 | $75,216.94 |
DisclosureSEC source: 0001209191-19-039547 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,774,346 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.32 to $7.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 19:44 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 10,000 | $8.25 | $82,485.00 |
DisclosureSEC source: 0001209191-19-034201 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,764,240 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.05 to $8.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 18:03 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001209191-19-004478 · doc4.xml · derivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 18:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 10,000 | $11.80 | $118,039.00 |
DisclosureSEC source: 0001209191-18-058692 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,754,240 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.64 to $12.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2018 Filed Aug 13, 2018 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 3,159 | $11.77 | $37,168.16 |
DisclosureSEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,744,240 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.61 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 2,579 | $11.94 | $30,796.35 |
DisclosureSEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,741,081 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:41 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 4,262 | $11.93 | $50,855.46 |
DisclosureSEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,738,502 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $12.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries C Convertible Preferred Stock · Derivative | 29,936 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 6 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 29,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F5 · derivative.underlying_shares: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries B Convertible Preferred Stock · Derivative | 125,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 5 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 125,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,020,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 4 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 2,020,202 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | PurchaseCommon Stock | 66,666 | $15.00 | $999,990.00 |
DisclosureSEC source: 0000899243-18-007987 · doc4.xml · nonDerivative · entry 2 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,734,240 F3 · shares: Represents shares purchased in the Issuer's initial public offering. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 21:27 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | ConversionCommon Stock | 2,175,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007987 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,667,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock. F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.